The absorption and elimination of orally administered (14C)hyoscine N-butylbromide (butylscopolamine)

H Vapaatalo et al. J Pharm Pharmacol. 1975 Jul.

. 1975 Jul;27(7):542-3.

doi: 10.1111/j.2042-7158.1975.tb09503.x.

No abstract available

Similar articles

Intestinal absorption, intestinal distribution, and excretion of (14C) labelled hyoscine N-butylbromide (butylscopolamine) in the rat.
Pentikäinen P, Penttilä A, Vapaatalo H, Hackman R. Pentikäinen P, et al. J Pharm Pharmacol. 1973 May;25(5):371-5. doi: 10.1111/j.2042-7158.1973.tb10030.x. J Pharm Pharmacol. 1973. PMID: 4146391 No abstract available.
The gastrointestinal absorption and the excretion of H3-butylscopolamine (hyoscine butylbromide) in man.
Hellström K, Rosén A, Söderlund K. Hellström K, et al. Scand J Gastroenterol. 1970;5(7):585-92. Scand J Gastroenterol. 1970. PMID: 5474428 No abstract available.
Oral hyoscine butylbromide for irritable bowel syndrome?
Gibbons D. Gibbons D. Br Med J. 1979 Mar 17;1(6165):752. doi: 10.1136/bmj.1.6165.752-b. Br Med J. 1979. PMID: 435769 Free PMC article. No abstract available.
Oral hyoscine butylbromide for irritable bowel syndrome?
Herxheimer A, Misiewicz JJ. Herxheimer A, et al. Br Med J. 1979 Mar 17;1(6165):752. doi: 10.1136/bmj.1.6165.752. Br Med J. 1979. PMID: 435770 Free PMC article. No abstract available.
Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain.
Tytgat GN. Tytgat GN. Drugs. 2007;67(9):1343-57. doi: 10.2165/00003495-200767090-00007. Drugs. 2007. PMID: 17547475 Review.

The BUSCOPAN study: a randomized-controlled non-inferiority trial of a continuous butylscopolamine infusion versus placebo in patients with a renal colic not responding to oral non-steroidal anti-inflammatory drugs.
Weltings S, Buddingh KT, van Diepen DC, Pelger RCM, Putter H, Rad M, Schout BMA, Roshani H. Weltings S, et al. World J Urol. 2021 Jul;39(7):2747-2752. doi: 10.1007/s00345-020-03460-0. Epub 2020 Sep 19. World J Urol. 2021. PMID: 32949255 Free PMC article. Clinical Trial.